Lilly's New Weight-Loss Drug Records 1,390 Prescriptions, Achieves 8.8% Weight Loss
Eli Lilly's new weight-loss pill garnered roughly 1,390 US prescriptions in its first week, versus Novo Nordisk's 113,000. Its oral GLP-1 candidate Foundayo met non-inferiority for major cardiovascular events in a 2,749-patient Phase 3 trial (hazard ratio 0.84) and showed a 1.6-point A1C drop plus 8.8% weight loss.
1. Early Market Uptake
Lilly secured approximately 1,390 prescriptions for its once-daily weight-loss pill in its first US week of sales after FDA approval on April 1, using a direct-to-consumer platform; by comparison, Novo Nordisk’s competing therapy recorded over 113,000 prescriptions, underscoring initial market penetration challenges.
2. Phase 3 ACHIEVE-4 Efficacy and Safety
In a 2,749-participant trial across 15 countries, Foundayo achieved non-inferiority for major cardiovascular events with a hazard ratio of 0.84, delivered a 1.6-point reduction in A1C after 52 weeks versus 1.0 with insulin glargine, and produced an average 8.8% weight loss (17.9 pounds) compared to a 3.1-pound gain in the insulin cohort; 10.6% discontinued due to gastrointestinal side effects.
3. Regulatory and Submission Timeline
Following FDA approval on April 1, Lilly prioritized launch through its own direct-to-consumer channel and plans to file Foundayo for Type 2 diabetes treatment by the end of the second quarter.
4. Adoption Constraints and Market Outlook
CEO David Ricks cautions that weight-loss therapies may ultimately reach only about half of eligible overweight and obese individuals due to healthcare system complexities and cost barriers, highlighting both substantial long-term demand and significant adoption hurdles.